TNFSF13B and systemic sclerosis: In a systemic sclerosis animal model, BAFF inhibition has been shown to attenuate fibrosis by reducing autoantibody levels and, importantly, by modulating cytokine profiles—specifically suppressing fibrogenic cytokines and increasing antifibrotic IFN-γ levels [151,152].